9342-8530 Quebec Inc DGCRF

RE: Transition to 16% royalties?

[ready2go1]

Not sure what the total is so far but I think GPRO did around $6 million last year. I look for them to transition to 16% sometime early next year. As I said before, there are a # of U.S. hospitals that are just getting up and running with the test and GPRO is working hard marketing the test in Europe and we will see it pay off shortly.
     I am interested to see if Gen-Probe goes into any additional detail on their plans during their call this month. In the past they have been very quiet when they are working on FDA approval for a test so I don't expect much; but looking ahead their should be a # of stories coming out on completed studies that will be published. I look for a few of them to move the share price like the GSK release did. I think there are at least 10-12 that have just been completed.
     As far as the trading goes, Over 22,000 shares traded in the U.S. yesterday and 5,000 today. I would like to see us push ahead and hit a 52 week high prior to news but the buyers are sitting back anytime they see a seller taking profits. I noticed this seller back when we were at 1.40 and he came back in when he saw the bids building. As soon as these buyers noticed the seller they pulled their orders in the hopes of picking up shares at a lower price. This is the pattern that continues to play out. I was excited when I saw all the orders the other day. We need one good day of heavy volume to clean things on and move on.
     (I wanted to add that some investors might read too much into any study that does not allow PCA3 to be the end all solution for prostate cancer testing. I know that GPRO is looking to expand their claims in the future but I am sure that it will require additional studies. In the mean time FDA approval will get us where we need to be.)